News Article
CDC ‘Dear Colleague’ Letter: FDA’s Drug Safety Communication on DTG
Posted on May 23, 2018
Blog: National Association of County & City Health Officials (NACCHO)
The Centers for Disease Control and Prevention released a ‘Dear Colleague’ letter regarding the U.S. Food and Drug Administration’s Drug Safety Communication on the potential risk of antiretroviral medication dolutegravir (DTG) associated neural tube birth defects. Read the letter.